Gruppo Lepetit

Ambi Inc.

Beth P Goldstein

Enrico Selva

Maurizio Denaro

Francesco Parenti

Peter Blackburn

Giovanni Cassani

Nicoletta Montanini

Graziella Beretta

Luigi Simioni

Angelo Borghi

Aldo Trani

Pietro Ferrari

Luciano Gastaldo

Gordon L Archer

Michael W Climo

Grazia Beretta

Vittorio Arioli

Debra J Cook

Rosamund Jean Williams

Gabriella Romano'

Sergio Bellini

Michael M Climo

Lysostaphin is an effective antibiotic in the treatment of staphylococcal infection. Large doses of lysostaphin or lysostaphin analogues are effective in short course, or even one dose administrations, in treating and eradicating staphylococcal infections, including those resistant to conventional antibiotics.

Method for the treatment of staphylococcal disease

The invention is directed to methods of treating diseases brought on by infection of the colon by C. difficile and also by colonization of vancomycin-resistant enterococci; the methods employ nisin and other lanthionine-containing bacteriocins (lanthocins) as active agents.

Method for the treatment of diarrheal disease and for eliminating

The invention concerns methods for killing antibiotic-resistant pathogenic bacteria which cause disease in humans and animals. In particular, the methods are directed to the killing of antibiotic-resistant or multi-drug resistant Streptococcus pneumoniae bacterial strains. The methods employ a lanthocin such as nisin or a variant thereof as bactericidal agent.

Method for the treatment of Streptococcus pneumoniae infection

The invention concerns methods for killing antibiotic-resistant pathogenic bacteria responsible for disease in humans and animals. The methods employ a lanthocin such as nisin as bactericidal agent.

Method for the control of antibiotic-resistant gram positive bacteria

Disclosed are compositions of nisin and GML as active ingredients for the killing of Helicobacter, as well as methods for eradicating Helicobacter colonization and treatment of Helicobacter infection which employ the GML/nisin compositions.

Compositions with activity against helicobacter

Central venous catheters loaded with antibiotics of the ramoplanin group

The present invention is directed to a new antibiotic substance denominated antibiotic GE 2270, the addition salts thereof, the pharmaceutical compositions thereof and their use as medicaments, particularly in the treatment of infectious diseases involving microorganisms susceptible to them.

Antibiotic GE 2270

Use of the antibiotic purpuromycin for the topical treatment of infectious vaginitis and topical dosage forms containing said product. The antibiotic purpuromycin is simultaneously active against the main causative agents of infectious vaginitis i.e.: Candida vaginalis, Trichomonas vaginalis and Gardnerella vaginalis.

Purpuromycin for the treatment of vaginal infections and pharmaceutical

Water soluble salts of purpuromycin, their use for the topical treatment of infectious vaginitis and topical dosage forms containing said products. Oral and parenteral formulations for administration of the water soluble purpuromycin salts. The water soluble salts of purpuromycin are simultaneously active against the main causative agents of infectious vaginitis i.e.: Candida vaginalis, Trichomonas vaginalis and Gardnerella vaginalis.

Water soluble salts of purpuromycin and pharmaceutical formulations

The present invention concerns a new antibiotic substance arbitrarily denominated antibiotic A 40926 complex and its factors antibiotic A 40926 factor A, antibiotic A 40926 factor B, antibiotic A 40926 factor B.sub.0, antibiotic A 40926 factor PA and antibiotic A 40926 factor PB, a process for producing them by culturing the new strain Actinomadura sp. ATCC 39727 or an A 40926 producing variant or mutant thereof and the use of these new antibiotic substances in the treatment of infectious diseases involving microorganisms susceptible to them. The antibiotic substances of the invention are glycopeptidic substances belonging to the vancomycin class of antibiotics which have binding capacity to Acyl-D-Alanyl-D-Alanine.

Antibiotic A 40926 complex and its pure factors PA, PB, A, B and B.sub.0

The present invention concerns a new antibiotic substance denominated antibiotic A 40926 mannosyl aglycon and the addition salts thereof, a process for preparing it from antibiotic A 40926 complex or a factor thereof, and its use in the treatment of infectious disease involving microorganisms susceptible to it.

Growing community of inventors

Tarrytown, NY, United States of America

Beth P Goldstein